Cargando…

Long-Term Corticotroph Function Following Cure of Cushing’s Syndrome

Introduction: Hyper- and hypofunction of the hypothalamic-pituitary-adrenal (HPA) axis in Cushing’s syndrome (CS) and Addison’s disease (AD) is associated with disturbances of classical feedback mechanisms. Time to recovery of adrenal function after CS remission depends on the etiology of CS and is...

Descripción completa

Detalles Bibliográficos
Autores principales: Schernthaner-Reiter, Marie Helene, Wolf, Peter, Micko, Alexander, Bögl, Magda, Beiglböck, Ms, Hannes, Scheuba, Christian, Riss, Philipp, Wolfsberger, Stefan, Kautzky-Willer, Alexandra, Luger, Anton, Vila, Greisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8090609/
http://dx.doi.org/10.1210/jendso/bvab048.1283
_version_ 1783687324366798848
author Schernthaner-Reiter, Marie Helene
Wolf, Peter
Micko, Alexander
Bögl, Magda
Beiglböck, Ms, Hannes
Scheuba, Christian
Riss, Philipp
Wolfsberger, Stefan
Kautzky-Willer, Alexandra
Luger, Anton
Vila, Greisa
author_facet Schernthaner-Reiter, Marie Helene
Wolf, Peter
Micko, Alexander
Bögl, Magda
Beiglböck, Ms, Hannes
Scheuba, Christian
Riss, Philipp
Wolfsberger, Stefan
Kautzky-Willer, Alexandra
Luger, Anton
Vila, Greisa
author_sort Schernthaner-Reiter, Marie Helene
collection PubMed
description Introduction: Hyper- and hypofunction of the hypothalamic-pituitary-adrenal (HPA) axis in Cushing’s syndrome (CS) and Addison’s disease (AD) is associated with disturbances of classical feedback mechanisms. Time to recovery of adrenal function after CS remission depends on the etiology of CS and is longest after adrenal CS. To date there are no data on the recovery of corticotroph function following CS remission, and the synacthen test is recommended for testing adrenal function in patients with hypopituitarism. Aim Here we aim to test corticotroph function after long-term cure of Cushing’s syndrome following bilateral adrenalectomy (BADx), compared to patients with primary glucocorticoid deficiency due the presence of 21-hydroxylase antibodies or adrenoleucodystrophy, a pathophysiological model of glucocorticoid and mineralocorticoid deficiency. Methods: We retrospectively evaluated data from patients with CS and AD attending our endocrine department between 2000 and 2020, using the following inclusion criteria: BADx performed for pituitary/ectopic/adrenal or occult CS or primary adrenal insufficiency confirmed either by the presence of 21-hydroxylase antibodies or genetically in adrenoleucodystrophy. Results: Full data were available for 93 patients: 43 patients with BADx due to CS (18 patients with pituitary CS, 14 patients with adrenal CS and 11 patients with ectopic/occult CS, F:M 29:14, mean age at BADx 45.4 years age range 13-74 years) and 50 patients with AD (47 cases with positive 21-hydroxylase antibodies, 3 cases with adrenoleucodystrophy, F:M ratio 27:23, mean age at diagnosis 35 years, age range 6-57 years). The observation period was 537.5 patient-years after BADx (mean 12.5 years, range 1-38 years) and 647 patient-years following AD diagnosis (mean 14.2 years, range 1-46 years). At the last visit, there were no differences between the hormone substitution regimes between the groups. ACTH concentrations during the whole observation period and also at the last visit were lowest in patients with adrenal CS (56.5 pg/ml) when compared to patients with AD (487 pg/ml, p<0.001), or with patients with pituitary CS (377.5 pg/mL, p=0.011). ACTH values in patients with AD in long-term follow-up were significantly higher when compared to all patients with CS (141 pg/mL, p<0.001). Conclusion: These data highlight a long-term defective corticotroph function in patients with CS following BADx. Low ACTH concentrations long term after BADx for adrenal CS corroborate that corticotroph function fails to recover after CS cure. In the light of these findings, the utility of the synacthen test for excluding secondary/tertiary adrenal insufficiency following CS remission is disputable and remains to be evaluated in future studies dedicated to CS cohorts.
format Online
Article
Text
id pubmed-8090609
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-80906092021-05-05 Long-Term Corticotroph Function Following Cure of Cushing’s Syndrome Schernthaner-Reiter, Marie Helene Wolf, Peter Micko, Alexander Bögl, Magda Beiglböck, Ms, Hannes Scheuba, Christian Riss, Philipp Wolfsberger, Stefan Kautzky-Willer, Alexandra Luger, Anton Vila, Greisa J Endocr Soc Neuroendocrinology and Pituitary Introduction: Hyper- and hypofunction of the hypothalamic-pituitary-adrenal (HPA) axis in Cushing’s syndrome (CS) and Addison’s disease (AD) is associated with disturbances of classical feedback mechanisms. Time to recovery of adrenal function after CS remission depends on the etiology of CS and is longest after adrenal CS. To date there are no data on the recovery of corticotroph function following CS remission, and the synacthen test is recommended for testing adrenal function in patients with hypopituitarism. Aim Here we aim to test corticotroph function after long-term cure of Cushing’s syndrome following bilateral adrenalectomy (BADx), compared to patients with primary glucocorticoid deficiency due the presence of 21-hydroxylase antibodies or adrenoleucodystrophy, a pathophysiological model of glucocorticoid and mineralocorticoid deficiency. Methods: We retrospectively evaluated data from patients with CS and AD attending our endocrine department between 2000 and 2020, using the following inclusion criteria: BADx performed for pituitary/ectopic/adrenal or occult CS or primary adrenal insufficiency confirmed either by the presence of 21-hydroxylase antibodies or genetically in adrenoleucodystrophy. Results: Full data were available for 93 patients: 43 patients with BADx due to CS (18 patients with pituitary CS, 14 patients with adrenal CS and 11 patients with ectopic/occult CS, F:M 29:14, mean age at BADx 45.4 years age range 13-74 years) and 50 patients with AD (47 cases with positive 21-hydroxylase antibodies, 3 cases with adrenoleucodystrophy, F:M ratio 27:23, mean age at diagnosis 35 years, age range 6-57 years). The observation period was 537.5 patient-years after BADx (mean 12.5 years, range 1-38 years) and 647 patient-years following AD diagnosis (mean 14.2 years, range 1-46 years). At the last visit, there were no differences between the hormone substitution regimes between the groups. ACTH concentrations during the whole observation period and also at the last visit were lowest in patients with adrenal CS (56.5 pg/ml) when compared to patients with AD (487 pg/ml, p<0.001), or with patients with pituitary CS (377.5 pg/mL, p=0.011). ACTH values in patients with AD in long-term follow-up were significantly higher when compared to all patients with CS (141 pg/mL, p<0.001). Conclusion: These data highlight a long-term defective corticotroph function in patients with CS following BADx. Low ACTH concentrations long term after BADx for adrenal CS corroborate that corticotroph function fails to recover after CS cure. In the light of these findings, the utility of the synacthen test for excluding secondary/tertiary adrenal insufficiency following CS remission is disputable and remains to be evaluated in future studies dedicated to CS cohorts. Oxford University Press 2021-05-03 /pmc/articles/PMC8090609/ http://dx.doi.org/10.1210/jendso/bvab048.1283 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Neuroendocrinology and Pituitary
Schernthaner-Reiter, Marie Helene
Wolf, Peter
Micko, Alexander
Bögl, Magda
Beiglböck, Ms, Hannes
Scheuba, Christian
Riss, Philipp
Wolfsberger, Stefan
Kautzky-Willer, Alexandra
Luger, Anton
Vila, Greisa
Long-Term Corticotroph Function Following Cure of Cushing’s Syndrome
title Long-Term Corticotroph Function Following Cure of Cushing’s Syndrome
title_full Long-Term Corticotroph Function Following Cure of Cushing’s Syndrome
title_fullStr Long-Term Corticotroph Function Following Cure of Cushing’s Syndrome
title_full_unstemmed Long-Term Corticotroph Function Following Cure of Cushing’s Syndrome
title_short Long-Term Corticotroph Function Following Cure of Cushing’s Syndrome
title_sort long-term corticotroph function following cure of cushing’s syndrome
topic Neuroendocrinology and Pituitary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8090609/
http://dx.doi.org/10.1210/jendso/bvab048.1283
work_keys_str_mv AT schernthanerreitermariehelene longtermcorticotrophfunctionfollowingcureofcushingssyndrome
AT wolfpeter longtermcorticotrophfunctionfollowingcureofcushingssyndrome
AT mickoalexander longtermcorticotrophfunctionfollowingcureofcushingssyndrome
AT boglmagda longtermcorticotrophfunctionfollowingcureofcushingssyndrome
AT beiglbockmshannes longtermcorticotrophfunctionfollowingcureofcushingssyndrome
AT scheubachristian longtermcorticotrophfunctionfollowingcureofcushingssyndrome
AT rissphilipp longtermcorticotrophfunctionfollowingcureofcushingssyndrome
AT wolfsbergerstefan longtermcorticotrophfunctionfollowingcureofcushingssyndrome
AT kautzkywilleralexandra longtermcorticotrophfunctionfollowingcureofcushingssyndrome
AT lugeranton longtermcorticotrophfunctionfollowingcureofcushingssyndrome
AT vilagreisa longtermcorticotrophfunctionfollowingcureofcushingssyndrome